Axsome hopes to end 2019 on a high with its depression drug AXS-05 while Lilly’s pegilodecakin is unlikely to redeem itself in lung cancer.
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
The failure of one of Allergan’s key pipeline projects puts the group’s chief executive under even more pressure.
Fresh from a mid-stage success in depression Axsome offers an unusual way to trade its upcoming phase III result.
The takeovers of Loxo and Celgene put M&A back on the agenda, and positive clinical readouts from Sage and Axsome add to the celebratory mood.
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.